Day surgery peritoneal dialysis catheter insertion
https://libcat.nshealth.ca/en/permalink/chpams35158
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1226
- Available Online
- View Pamphlet
This pamphlet reviews what to expect before, during and after surgery for the insertion of a peritoneal dialysis catheter. Information includes how to get your bowels ready for surgery, what to bring to the hospital on the day of surgery, care of your incision/exit site and keeping your bowels regular after surgery. Information about peritoneal dialysis teaching is also provided.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (18 p.) : digital, PDF file
- Subjects (MeSH)
- Hospital admission
- Peritoneal dialysis
- Kidney Diseases - surgery
- Preoperative Care
- Postoperative Care
- Subjects (LCSH)
- Peritoneal access
- Peritoneal dialysis
- Preoperative care
- Postoperative care
- Specialty
- Nephrology
- Hematology
- Abstract
- This pamphlet reviews what to expect before, during and after surgery for the insertion of a peritoneal dialysis catheter. Information includes how to get your bowels ready for surgery, what to bring to the hospital on the day of surgery, care of your incision/exit site and keeping your bowels regular after surgery. Information about peritoneal dialysis teaching is also provided.
- Responsibility
- prepared by: NSHA Renal Program
- Pamphlet Number
- 1226
Lanthanum (Fosrenol) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1466
- Available Online
- View Pamphlet
Lanthanum (LAN-tha-num) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. People with kidney disease are less able to remove phosphorus from the body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. This makes them weaker. Hemodialysis can remove some of the extra phosphorus, but medicin…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Lanthanum
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- Lanthanum (LAN-tha-num) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. People with kidney disease are less able to remove phosphorus from the body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. This makes them weaker. Hemodialysis can remove some of the extra phosphorus, but medicines such as lanthanam are often needed to help remove more. How to take the medicine and what side effects to watch for are reviewed. Fosrenol® is a brand name for lanthanum.
- Notes
- Previous title: Fosrenol (Lanthanum) and hemodialysis
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1466
Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1465
- Available Online
- View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Cinacalcet
- Renal Insufficiency, Chronic - drug therapy
- Hyperparathyroidism, Secondary - drug therapy
- Subjects (LCSH)
- Chronic renal failure
- Hyperparathyroidism
- Kidneys--Diseases--Treatment
- Abstract
- Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
- Notes
- Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1465
Sevelamer (Renagel) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1464
- Available Online
- View Pamphlet
Sevelamer (se-VEL-a-mer) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. People with kidney disease are less able to remove phosphorus from their body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. Hemodialysis can remove some of the extra phosphorus, but medicines such as sevelamer are often needed to help remove more. How to take sevelamer and what side effects to watch for are reviewe…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Sevelamer
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Abstract
- Sevelamer (se-VEL-a-mer) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. People with kidney disease are less able to remove phosphorus from their body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. Hemodialysis can remove some of the extra phosphorus, but medicines such as sevelamer are often needed to help remove more. How to take sevelamer and what side effects to watch for are reviewed. Renagel® is a brand name for sevelamer.
- Notes
- Previous title: Renagel (Sevelamer) and Hemodialysis
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1464
Over-the-counter medications & chronic kidney disease
https://libcat.nshealth.ca/en/permalink/chpams35643
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1636
- Available Online
- View Pamphlet
If you have chronic kidney disease, you need to be aware of certain over-the-counter medications that are your best choices and those that could cause unpleasant side effects. This pamphlet lists common ailments (e.g., cough and cold, fever or pain, allergies, upset stomach or heartburn, nausea or vomiting, diarrhea, constipation) and over-the-counter medications that are your best choices, their costs, and medications to stay away from. It also lists your best choices for multivitamins, creams…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([6] p.) : digital, PDF file
- Subjects (MeSH)
- Nonprescription Drugs
- Renal Insufficiency, Chronic - drug therapy
- Subjects (LCSH)
- Drugs, Nonprescription
- Chronic renal failure
- Specialty
- Medications
- Abstract
- If you have chronic kidney disease, you need to be aware of certain over-the-counter medications that are your best choices and those that could cause unpleasant side effects. This pamphlet lists common ailments (e.g., cough and cold, fever or pain, allergies, upset stomach or heartburn, nausea or vomiting, diarrhea, constipation) and over-the-counter medications that are your best choices, their costs, and medications to stay away from. It also lists your best choices for multivitamins, creams and ointments, and gives information on why herbal products are not recommended.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1636
24-hour urine collection : split daytime and nightime
https://libcat.nshealth.ca/en/permalink/chpams36496
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1940
- Available Online
- View Pamphlet
Step-by-step instructions are provided to collect a 24 hour split urine sample. Locations for drop offs (24 hour access) are included.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Urine Specimen Collection
- Specimen Handling
- Subjects (LCSH)
- Diagnostic specimens
- Urine--Collection and preservation
- Abstract
- Step-by-step instructions are provided to collect a 24 hour split urine sample. Locations for drop offs (24 hour access) are included.
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1940
Oral irons and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35375
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1469
- Available Online
- View Pamphlet
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Alternate Title
- Oral irons and CKD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Renal Insufficiency, Chronic - drug therapy
- Anemia, Iron-Deficiency - drug therapy
- Abstract
- Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1469
Bowel preparation for chronic kidney disease before colonoscopy
https://libcat.nshealth.ca/en/permalink/chpams35387
Nova Scotia Health Authority. Renal Program, Nova Scotia Health Authority. Pharmacy Services.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1475
- Available Online
- View Pamphlet
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Nova Scotia Health Authority. Pharmacy Services
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Cathartics
- Colonoscopy
- Renal Insufficiency, Chronic
- Subjects (LCSH)
- Laxatives
- Colonoscopy
- Chronic renal failure
- Specialty
- Medications
- Nephrology
- Abstract
- This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
- Responsibility
- Prepared by: NSHA Renal Program Educators and Pharmacists
- Pamphlet Number
- 1475
Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1493
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1493
Injectable iron and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35408
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1495
- Available Online
- View Pamphlet
If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Dialysis
- Iron - therapeutic use
- Kidney Diseases
- Anemia, Iron-Deficiency
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure--Complications
- Iron deficiency anemia
- Abstract
- If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication. The French version of this pamphlet 2161, "Fer injectable et insuffisance rénale chronique (IRC)," is also available.
- Notes
- Previous title: Injectable iron sucrose and chronic kidney disease
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1495
Dalteparin (Fragmin) to prevent clotting during hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams35807
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1760
- Available Online
- View Pamphlet
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Dalteparin
- Renal Dialysis
- Subjects (LCSH)
- Hemodialysis
- Blood--coagulation
- Specialty
- Nephrology
- Abstract
- Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1760
Rocaltrol® (calcitriol) and hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1468
- Available Online
- View Pamphlet
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Pharmacy Services
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Calcitriol
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. Rocaltrol® is a brand name for calcitriol.
- Responsibility
- Prepared by: Renal Pharmacy Team, NSHA Renal Program
- Pamphlet Number
- 1468
One-Alpha® (alfacalcidol) and hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1470
- Available Online
- View Pamphlet
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Pharmacy Services
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. One-Alpha® is a brand name for alfacalcidol.
- Responsibility
- Prepared by: Renal Pharmacy Team, NSHA Renal Program
- Pamphlet Number
- 1470
Care of your peritoneal dialysis catheter
https://libcat.nshealth.ca/en/permalink/chpams36677
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 0352
- Available Online
- View Pamphlet
This pamphlet reviews how to protect your peritoneal dialysis catheter. Information includes how to care for your incision (cut) or exit site after surgery and keeping your bowels regular. Information about when to call your VON or home care nurse is also given. The French version of this pamphlet 2098, "Prendre soin de votre cathéter de dialyse péritonéale", is also available.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (4 p.) : digital, PDF file
- Subjects (MeSH)
- Peritoneal Dialysis
- Kidney Diseases - surgery
- Subjects (LCSH)
- Peritoneal access
- Peritoneal dialysis
- Specialty
- Nephrology
- Hematology
- Abstract
- This pamphlet reviews how to protect your peritoneal dialysis catheter. Information includes how to care for your incision (cut) or exit site after surgery and keeping your bowels regular. Information about when to call your VON or home care nurse is also given. The French version of this pamphlet 2098, "Prendre soin de votre cathéter de dialyse péritonéale", is also available.
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 0352
Prendre soin de votre cathéter de dialyse péritonéale
https://libcat.nshealth.ca/en/permalink/chpams36721
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 2098
- Available Online
- View Pamphlet
La brochure porte sur la façon de protéger votre cathéter de dialyse péritonéale. On y traite des soins de l’incision (coupure) ou du point d'émergence cutané (point de sortie) après l’opération et du maintien de la régularité intestinale. On vous indique aussi quand appeler l’infirmière de l’Ordre de Victoria du Canada (VON) ou des soins à domicile. ; This pamphlet is a French translation of "Care of Your Peritoneal Dialysis Catheter" pamphlet 0352. This pamphlet reviews how to protect your pe…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Alternate Title
- Care of your peritoneal dialysis catheter
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- French
- Physical Description
- 1 electronic document (4 p.) : digital, PDF file
- Subjects (MeSH)
- Peritoneal Dialysis
- Kidney Diseases - surgery
- Subjects (LCSH)
- Peritoneal access
- Peritoneal dialysis
- Specialty
- Nephrology
- Hematology
- Abstract
- La brochure porte sur la façon de protéger votre cathéter de dialyse péritonéale. On y traite des soins de l’incision (coupure) ou du point d'émergence cutané (point de sortie) après l’opération et du maintien de la régularité intestinale. On vous indique aussi quand appeler l’infirmière de l’Ordre de Victoria du Canada (VON) ou des soins à domicile.
- This pamphlet is a French translation of "Care of Your Peritoneal Dialysis Catheter" pamphlet 0352. This pamphlet reviews how to protect your peritoneal dialysis catheter. Information includes how to care for your incision (cut) or exit site after surgery and keeping your bowels regular. Information about when to call your VON or home care nurse is also given.
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 2098
Fer injectable et insuffisance rénale chronique (IRC)
https://libcat.nshealth.ca/en/permalink/chpams37473
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 2161
- Available Online
- View Pamphlet
Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygè…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Alternate Title
- Injectable iron and chronic kidney disease (CKD)
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- French
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Dialysis
- Iron - therapeutic use
- Kidney Diseases
- Anemia, Iron-Deficiency
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure--Complications
- Iron deficiency anemia
- Abstract
- Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygène. Ce dépliant explique comment prendre du fer injectable, ses effets possibles et comment le conserver.
- This pamphlet is a French translation of the English pamphlet 1495, "Injectable Iron and Chronic Kidney Disease (CKD)". If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication.
- Notes
- Previous title: Injectable iron sucrose and chronic kidney disease
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 2161
How to do a twin bag exchange
https://libcat.nshealth.ca/en/permalink/chpams34482
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 0633
- Available Online
- View Pamphlet
This pamphlet was prepared to help you in doing your own peritoneal dialysis at home. Illustrations are used to explain how to do a twin bag™ exchange. Information provided in the pamphlet includes how to deal with drain, fill, and mechanical problems. The Simplified Chinese version of this pamphlet 2214, is also available.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Peritoneal Dialysis
- Subjects (LCSH)
- Peritoneal dialysis
- Abstract
- This pamphlet was prepared to help you in doing your own peritoneal dialysis at home. Illustrations are used to explain how to do a twin bag™ exchange. Information provided in the pamphlet includes how to deal with drain, fill, and mechanical problems. The Simplified Chinese version of this pamphlet 2214, is also available.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 0633
Treatment of high potassium with Kayexalate powder in hemodialysis patients
https://libcat.nshealth.ca/en/permalink/chpams35337
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1445
- Available Online
- View Pamphlet
People with kidney disease have a higher chance of having high potassium levels. High potassium levels may lead to an irregular heartbeat or cause problems with muscles and nerves. Kayexalate® is a drug that treats high potassium levels. This pamphlet explains how to take Kayexlate®, side effects, and how to store this medication.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Dialysis
- Polystyrene sulfonic acid
- Hyperkalemia
- Subjects (LCSH)
- Drugs
- Low-potassium diet
- Specialty
- Nephrology
- Medications
- Abstract
- People with kidney disease have a higher chance of having high potassium levels. High potassium levels may lead to an irregular heartbeat or cause problems with muscles and nerves. Kayexalate® is a drug that treats high potassium levels. This pamphlet explains how to take Kayexlate®, side effects, and how to store this medication.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1445
[How to do a twin bag exchange]
https://libcat.nshealth.ca/en/permalink/chpams37434
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 2214
- Available Online
- View Pamphlet
This pamphlet is a Simplified Chinese translation of the English 0633, "How to do a Twin Bag™ Exchange". This pamphlet was prepared to help you in doing your own peritoneal dialysis at home. Illustrations are used to explain how to do a twin bag™ exchange. Information provided in the pamphlet includes how to deal with drain, fill, and mechanical problems.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- Simplified Chinese
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Peritoneal Dialysis
- Subjects (LCSH)
- Peritoneal dialysis
- Abstract
- This pamphlet is a Simplified Chinese translation of the English 0633, "How to do a Twin Bag™ Exchange". This pamphlet was prepared to help you in doing your own peritoneal dialysis at home. Illustrations are used to explain how to do a twin bag™ exchange. Information provided in the pamphlet includes how to deal with drain, fill, and mechanical problems.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 2214
Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke
https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 2217
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Neoplasms
- Stroke
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Cancer
- Cerebrovascular disease
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 2217
